Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 2/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18065640 | 0.93 | DDB1 (0.41) | DDB1CRBNADORA1USP2SMN1; SMN2 | |
| SCHEMBL18618412 | 0.89 | ADORA1 (0.42) | DDB1CRBNADORA1USP2SMN1; SMN2 | |
| SCHEMBL29450194 | 0.89 | ADORA1 (0.42) | DDB1CRBNADORA1USP2SMN1; SMN2 | |
| SCHEMBL13047175 | 0.89 | ADORA1 (0.42) | DDB1CRBNADORA1USP2SMN1; SMN2 | |
| SCHEMBL1974887 | 0.84 | ADORA1 (0.41) | DDB1CRBNADORA1USP2SMN1; SMN2 | |
| SCHEMBL18286044 | 0.83 | OPRM1 (0.38) | L3MBTL1ALOX15ALDH1A1LMNA | |
| SCHEMBL14990611 | 0.81 | ADORA1 (0.39) | DDB1CRBNADORA1USP2SMN1; SMN2 | |
| SCHEMBL14701441 | 0.81 | ADORA1 (0.40) | DDB1CRBNADORA1USP2SMN1; SMN2 | |
| SCHEMBL442966 | 0.80 | SMN1; SMN2 (0.45) | ADORA1USP2SMN1; SMN2KDM4EL3MBTL1 | |
| SCHEMBL2206945 | 0.78 | SMN1; SMN2 (0.46) | ADORA1USP2SMN1; SMN2KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-13 | — | — | US | disclosed |
| US-12195445-B2 | 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-01-14 | — | — | US | disclosed |
| CN-113272293-B | 2-Amino-N-heteroaryl-nicotinamide as NAV1.8 inhibitor | 默沙东有限责任公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20220289710-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-09-15 | — | — | US | disclosed |
| US-11377438-B2 | 2-amino-n-heteroaryl-nicotinamides as Nav1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210387966-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-16 | — | — | US | disclosed |
| EP-3873893-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20150225355-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150225355-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150197533-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2015-07-16 | — | — | US | disclosed |
| US-20150197493-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2015-07-16 | — | — | US | disclosed |
| US-20150197533-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2015-07-16 | — | — | US | disclosed |
| US-20150197493-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2015-07-16 | — | — | US | disclosed |
| EP-2373653-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010063634-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195445-B2 | 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors | SCN8A, SCN2A, SCN1A | DDB1 4671/4885CRBN 4158/4885ADORA1 583/4885 |
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | DDB1 4671/4885CRBN 4158/4885ADORA1 583/4885 |
| US-11377438-B2 | 2-amino-n-heteroaryl-nicotinamides as Nav1.8 inhibitors | SCN8A, SCN2A, SCN1A | DDB1 4671/4885CRBN 4158/4885ADORA1 583/4885 |
| US-20220289710-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | DDB1 4671/4885CRBN 4158/4885ADORA1 583/4885 |
| US-20210387966-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | DDB1 4671/4885CRBN 4158/4885ADORA1 583/4885 |
| US-20150225355-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | DDB1 386/4885CRBN 1918/4885ADORA1 1069/4885 |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | DDB1 3189/4885CRBN 1774/4885ADORA1 4192/4885 |
| US-20150197533-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | DDB1 386/4885CRBN 1918/4885ADORA1 1069/4885 |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | DDB1 2232/4885CRBN 1419/4885ADORA1 3731/4885 |
| US-20150197493-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | DDB1 386/4885CRBN 1918/4885ADORA1 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.